Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1

AIMS/HYPOTHESIS: Peroxisome proliferator-activated receptor (PPAR) γ agonists are used increasingly in the treatment of type 2 diabetes. In the context of renal disease, PPARγ agonists reduce microalbuminuria in diabetic nephropathy; however, the mechanisms underlying this effect are unknown. Glomer...

Full description

Saved in:

Bibliographic Details
Published in:	Diabetologia
Main Authors:	Lennon, R., Welsh, G.I., Singh, A., Satchell, S.C., Coward, R.J., Tavaré, J.M., Mathieson, P.W., Saleem, M.A.
Format:	Artigo
Language:	Inglês
Published:	2009
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC7614273/ https://ncbi.nlm.nih.gov/pubmed/19533082 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-009-1423-7
Tags:	Add Tag No Tags, Be the first to tag this record!

Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1

Similar Items